Generic sofosbuvir and daclatasvir for treatment of hepatitis C virus infection in patients with sickle cell disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Generic sofosbuvir and daclatasvir for treatment of hepatitis C virus infection in patients with sickle cell disease ; volume:14 ; number:1 ; day:9 ; month:9 ; year:2024 ; pages:1-7 ; date:12.2024
Egyptian liver journal ; 14, Heft 1 (9.9.2024), 1-7, 12.2024

Creator: Moustafa, Ahmed
AbdAllah, Mohamed
Akel, Wafaa El
Wahed, Sherif
Alem, Shereen Abdel
Esmat, Gamal

Contributor: SpringerLink (Online service)

DOI: 10.1186/s43066-024-00371-2

URN: urn:nbn:de:101:1-2411232121210.611822954738

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Moustafa, Ahmed
AbdAllah, Mohamed
Akel, Wafaa El
Wahed, Sherif
Alem, Shereen Abdel
Esmat, Gamal
SpringerLink (Online service)

Other Objects (12)

Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor

Acute Hepatitis C Virus Infection Treated with Daclatasvir/Sofosbuvir in a 9-Year-Old Boy

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Addendum zum Auftrag A16-48

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Sofosbuvir/Velpatasvir/Voxilaprevir (Chronische Hepatitis C) : Addendum zum Auftrag A17-35

Ledipasvir/Sofosbuvir eradicates hepatitis C in an immunodeficient STAT3-GOF patient

Sofosbuvir (chronische Hepatitis C bei Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient

Sofosbuvir (chronische Hepatitis C bei Kindern) : Nutzenbewertung gemäß § 35a SGB V

Sofosbuvir/Velpatasvir/ Voxilaprevir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor

Acute Hepatitis C Virus Infection Treated with Daclatasvir/Sofosbuvir in a 9-Year-Old Boy

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Addendum zum Auftrag A16-48

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Sofosbuvir/Velpatasvir/Voxilaprevir (Chronische Hepatitis C) : Addendum zum Auftrag A17-35

Ledipasvir/Sofosbuvir eradicates hepatitis C in an immunodeficient STAT3-GOF patient

Sofosbuvir (chronische Hepatitis C bei Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient

Sofosbuvir (chronische Hepatitis C bei Kindern) : Nutzenbewertung gemäß § 35a SGB V

Sofosbuvir/Velpatasvir/ Voxilaprevir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor

Acute Hepatitis C Virus Infection Treated with Daclatasvir/Sofosbuvir in a 9-Year-Old Boy

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Addendum zum Auftrag A16-48

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Sofosbuvir/Velpatasvir/Voxilaprevir (Chronische Hepatitis C) : Addendum zum Auftrag A17-35

Ledipasvir/Sofosbuvir eradicates hepatitis C in an immunodeficient STAT3-GOF patient

Sofosbuvir (chronische Hepatitis C bei Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient

Sofosbuvir (chronische Hepatitis C bei Kindern) : Nutzenbewertung gemäß § 35a SGB V

Sofosbuvir/Velpatasvir/ Voxilaprevir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Generic sofosbuvir and daclatasvir for treatment of hepatitis C virus infection in patients with sickle cell disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor

Acute Hepatitis C Virus Infection Treated with Daclatasvir/Sofosbuvir in a 9-Year-Old Boy

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Addendum zum Auftrag A16-48

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Sofosbuvir/Velpatasvir/Voxilaprevir (Chronische Hepatitis C) : Addendum zum Auftrag A17-35

Ledipasvir/Sofosbuvir eradicates hepatitis C in an immunodeficient STAT3-GOF patient

Sofosbuvir (chronische Hepatitis C bei Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient

Sofosbuvir (chronische Hepatitis C bei Kindern) : Nutzenbewertung gemäß § 35a SGB V

Sofosbuvir/Velpatasvir/ Voxilaprevir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor

Acute Hepatitis C Virus Infection Treated with Daclatasvir/Sofosbuvir in a 9-Year-Old Boy

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Addendum zum Auftrag A16-48

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Sofosbuvir/Velpatasvir/Voxilaprevir (Chronische Hepatitis C) : Addendum zum Auftrag A17-35

Ledipasvir/Sofosbuvir eradicates hepatitis C in an immunodeficient STAT3-GOF patient

Sofosbuvir (chronische Hepatitis C bei Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient

Sofosbuvir (chronische Hepatitis C bei Kindern) : Nutzenbewertung gemäß § 35a SGB V

Sofosbuvir/Velpatasvir/ Voxilaprevir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor

Acute Hepatitis C Virus Infection Treated with Daclatasvir/Sofosbuvir in a 9-Year-Old Boy

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Addendum zum Auftrag A16-48

Sofosbuvir/Velpatasvir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Sofosbuvir/Velpatasvir/Voxilaprevir (Chronische Hepatitis C) : Addendum zum Auftrag A17-35

Ledipasvir/Sofosbuvir eradicates hepatitis C in an immunodeficient STAT3-GOF patient

Sofosbuvir (chronische Hepatitis C bei Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient

Sofosbuvir (chronische Hepatitis C bei Kindern) : Nutzenbewertung gemäß § 35a SGB V

Sofosbuvir/Velpatasvir/ Voxilaprevir (chronische Hepatitis C) : Nutzenbewertung gemäß § 35a SGB V

Related objects

Reset password